Allometric-Pace Study

Sponsor
Medtronic Cardiac Rhythm and Heart Failure (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05766462
Collaborator
(none)
70
15.4

Study Details

Study Description

Brief Summary

The goal of this observational study is to improve quality of life in sinus node dysfunction patients by utilizing allometric lower rate pacing (or called personalized lower rate, PLR) in standard commercially available dual-chamber pacemakers.

The primary objective is to achieve a significant improvement in patients' quality of life with use of PLR pacing in comparison with the control group with nominal lower rate in patients with implanted dual-chamber pacemaker.

The secondary objectives are to assess cardiac functional changes in echocardiography of ventricular mechanical performance with a PLR pacing in comparison with the control group with nominal lower rate, and to assess the viability of using elevated blood pressure as a marker for undetected bradycardia and providing allometric rate to correct bradycardia-related increase in arterial systolic blood pressure.

Condition or Disease Intervention/Treatment Phase
  • Other: Pacemaker lower rate setting

Study Design

Study Type:
Observational
Anticipated Enrollment :
70 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Utilization of Personalized Pacing to Improve Quality of Life in Sinus Node Dysfunction Patients
Anticipated Study Start Date :
Mar 20, 2023
Anticipated Primary Completion Date :
Jun 30, 2024
Anticipated Study Completion Date :
Jun 30, 2024

Arms and Interventions

Arm Intervention/Treatment
PLR group

The pacemaker lower rate of PLR group will be set as 75 bpm and might be adjusted according to physician diagnosis based on patients situation.

Other: Pacemaker lower rate setting
Pacemaker lower rate is set by physician and may be adjusted according to the physician diagnosis.

control group

The pacemaker lower rate of control group will be set as 60 bpm.

Outcome Measures

Primary Outcome Measures

  1. Life quality measurement [Within three months after the surgery]

    SF-36 questionnaire score will be used as the criteria.

Secondary Outcome Measures

  1. Cardiac functional changes [Within three months after the surgery]

    LVEF will be measured

  2. To assess the correlation of elevated blood pressure and bradycardia. [Within three months after the surgery]

    24 hour ambulatory blood pressure will be measured.

Eligibility Criteria

Criteria

Ages Eligible for Study:
60 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients are at age of equal to or more than 60 years old

  • Patients have plan to implant dual-chamber pacemaker

  • Resting sinus heart rate is equal or less than 60 bpm, or average heart rate detected through 24-hour dynamic electrocardiogram is equal or less than 60 bpm

  • Patients have diagnosis of SND. If patients have both sinus node dysfunction and AV block, conduction system pacing shall be available

  • Patients have a history of hypertension, two times of blood pressure measurements at office visit are equal to or more than 130 mmHg in systolic blood pressure, diastolic pressure is equal or less than 80 bpm

Exclusion Criteria:
  • Patients have or possible concomitant a diagnosis of heart failure, either reduced EF or preserved EF

  • Patients have persistent or chronic atrial fibrillation or clinically significant paroxysmal atrial fibrillation

  • Previously diagnosed with a history of organic heart disease: including congenital heart disease, coronary heart disease, old myocardial infarction, dilated cardiomyopathy, hypertrophic cardiomyopathy, cardiac amyloidosis, long QT syndrome, etc.

  • Patients have a known secondary cause of hypertension

  • Patients have hospitalization of a hypertensive emergency in the previous year

  • Patients have a history of renal disease or renal-artery diseases

  • Severe hepatic or renal dysfunction

  • Active acute infection

  • Patients cannot submit a signed informed consent form

  • Patients are pregnant or plan to be pregnant during study period

  • Patients participate in another study that will confound this study

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Medtronic Cardiac Rhythm and Heart Failure

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Medtronic Cardiac Rhythm and Heart Failure
ClinicalTrials.gov Identifier:
NCT05766462
Other Study ID Numbers:
  • Allometric-Pace Study
First Posted:
Mar 13, 2023
Last Update Posted:
Mar 13, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 13, 2023